Racial and Ethnic Diversity Plan (REDP) for Clinical Trials to Sponsors Submitting IND/INDA to FDA

Racial and Ethnic Diversity Plans for Biopharmaceutical Companies

FDA has now required biopharmaceutical companies to include a racial and ethnic diversity plan (REDP) in their IND submissions. The FDA has issued guidance to the industry on what is expected in this plan for ensuring all racial and ethnic populations are proportionally represented in their clinical trials across all phases based on the prevalence of the disease under investigation. 

Jeeva offers the development and delivery of REDP as a “fee for service” to support our sponsors. 

Racial and Ethnic Diversity Plans Image - REDP
Latest Conference on DEIA in Clinical Trials - REDP

Check our latest Conference on DEIA in Clinical Trials

Driving Global Diversity, Equity, Inclusion, and Access in Clinical Trials: Jeeva’s Vision and Insights Shared at Outsourcing Conference

As an invited speaker, Jeeva founder and CEO outlined his vision for helping sponsors, CROs, and Sites achieve global diversity, equity, inclusion, and access at the outsourcing clinical trials conference in Valley Forge, PA, in May 2023. Dr. Rajasimha also participated in a panel discussion moderated by the rare disease diversity coalition. 

Click here to download the presentation “What does it take to truly achieve DEIA in clinical” 

Compliance Programs Supported

Ready to Explore Jeeva REDP for Clinical Trials?

Jeeva REDP for clinical trials is designed to assist and support our sponsors throughout the process. Our expertise in this area allows us to offer comprehensive solutions tailored to each trial’s unique needs.